View : 54 Download: 0
An investigation of the traditional algorithm-based designs for phase 1 cancer clinical trials
- An investigation of the traditional algorithm-based designs for phase 1 cancer clinical trials
- Kang S.-H.; Ahn C.W.
- Ewha Authors
- Issue Date
- Journal Title
- Therapeutic Innovation & Regulatory Science
- vol. 36, no. 4, pp. 865 - 873
- Algorithm-based design; Dose finding studies; Maximum tolerated dose; Phase 1 cancer trials; Toxicity
- SCIE; SCOPUS
- The primary aim of a phase 1 cancer clinical trial is to determine the maximum tolerated dose of a new drug. Although the continual reassessment method is shown to have better operating characteristics than traditional designs, traditional designs are still widely used in practice. Kang and Ahn (1) developed an algorithm to compute the exact distribution of the maximum tolerated dose (MTD) in traditional designs with dose deescalation and investigated the expected toxicity rate at the MTD with the algorithm. In this paper, using the exact formulae derived by Lin and Shih (2), we study the expected toxicity rate at the MTD and the expected number of patients with toxicity and patients required when the hyperbolic tangent and the logistic functions are used as the unknown dose-toxicity curves. We consider the expected toxicity rate both without and with dose deescalation. No further study was done before in cases where dose level zero is chosen as the MTD. Since, in real practice, dose levels are lowered for adjustment and a new trial is conducted when dose level zero is decided as the MTD, we also incorporate this dose adjustment. © 2002, Drug Information Association. All rights reserved.
- Appears in Collections:
- 자연과학대학 > 통계학전공 > Journal papers
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.